Patient-Derived Organoids for Prediction of Sensitivity to Postoperative Adjuvant Chemotherapy for Gastric Cancer

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000028889

Enrollment

Unknown

Registered

2020-01-06

Start date

2020-01-01

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cance

Interventions

Case series:Non-interventional study

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Male and female patients aged 18-75 years; 2. Gastric cancer confirmed by histopathologic or cytopathologic analysis; 3. Postoperative pathological TNM stage: stage II (i.e., cT1- 2N1-3M0/cT3-4N0M0) or III (i.e., cT3-4aN1-3M0) gastric cancer (UICC 7th edition); 4. Received D2 gastrectomy, and planned to receive postoperative adjuvant chemotherapy; 5. ECOG Physical Condition Score (PS) score 0-1; 6. Expected overall survival >= 3 months; 7. Informed consent signed by the patients.

Exclusion criteria

Exclusion criteria: 1. Patients that have received chemotherapy, radiation or immunotherapy; 2. Patients with other malignant tumor in the last five years, except for cured skin cancer; 3. With mental disorders or cardiovascular diseases; 4. Patients have already been enrolled in other clinical trials in the last four weeks; 5. Pregnant woman, or woman with a plan for pregnancy in one year.

Design outcomes

Primary

Measure	Time frame
Progression free survival, PFS;Overall survival, OS;	—

Countries

China

Contacts

Public ContactYulong He

The Seventh Affiliated Hospital, Sun Yat-Sen University

heyulong@mail.sysu.edu.cn+86 0755-81206999

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026